LUMO

Lumos Pharma, Inc. (LUMO) | Rumor.io

Lumos Pharma

LUMO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about LUMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 19

*LUMO* has seen a sharp pullback from highs, with a current market cap of around 37.5K MC, and is undergoing consolidation.
The top holder of *LUMO* has a 5% stake, with some individual holding 8.5% through multiple wallets.
*LUMO* has experienced a strong recovery after a significant dip, retesting the 50K MC zone.

Generated by AI

Sentiment

Of the messages about LUMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.92% +10.02
Bearish	—	—	—	4.08% -10.02

Bullish· Feb 14

$LUMO is breaking ATHs and has a bullish chart, with over 550 holders and top 25 on DEX.
The project has a strong narrative, created by the same mind behind $Pippin, which touched 600M, suggesting similar potential.
Momentum is building, with the next leg expected to be huge, potentially reaching 500k and entering Big Whales territory.

Bearish· May 20

The release of the LumoKit has led to a sell-off in $LUMO, with early buyers quickly selling their shares.
The hype surrounding $LUMO has been short-lived, with the asset experiencing a significant price drop after the toolkit was shipped.
$LUMO's community has been criticized for being overly aggressive and confrontational, with some users accusing the team of being unresponsive to criticism and blocking users who speak out against them.

Generated by AI

Topics

Of the messages about LUMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	44.44%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	55.56%

Announcements· Dec 20

NewLink Genetics' Ebola vaccine, Ervebo, has been approved by the FDA for individuals 18 years and older.
The approval triggers a priority review voucher, which NewLink has a substantial economic interest in, and the company is expected to receive escalating royalties on sales.
The FDA's approval is a significant development for NewLink, with the company's stock surging over 7% in response, and is expected to provide substantial economic interest to the company.

Technical Analysis· Feb 21

$LUMO is in a downtrend with recent consolidation, with support around 0.0065 and resistance near 0.0090, and RSI approaching oversold levels.
$LUMO is showing bullish momentum with support around 0.0100 and resistance at 0.0125, with RSI above 70 and MACD showing a bullish crossover.
$LUMO is forming a potential double bottom pattern, indicating a possible upward breakout, with RSI rising and MACD showing a bullish crossover, and support around 0.010 and resistance at 0.015.

Generated by AI

Community

Of the messages about LUMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	22.47%
Newcomers	—	—	—	77.53%

Regulars· Nov 14

The interim results from two Phase 2 trials evaluating oral LUM-201 for moderate pediatric growth hormone deficiency showed an encouraging response, but the final analysis is awaited.
Lumos Pharma reported a loss of $0.86, which was better than the consensus estimate of ($1.01), and the company announced encouraging interim results from two Phase 2 trials.
The stock price declined by -22.4% after the company announced encouraging interim results from two Phase 2 trials evaluating oral LUM-201 for moderate pediatric growth hormone deficiency.

Newcomers· Feb 7

$LUMO is exhibiting a bullish chart, with a potential AI-driven parabola forming, according to some users.
The consolidation pattern in $LUMO's chart suggests potential upside if a certain support level holds, and some users are optimistic about its prospects.
$LUMO is among the AI stocks that some users are looking at for potential growth, alongside $SNAI and $NEUR.

Generated by AI

Also Discussed

Investors talking about LUMO also mention

#	Name	Attention
1	Sarmaya Thematic ETFLENS	0.01%new
2	ARC - ARC Document Solutions, Inc.	——
3	Alchemist AIALCH	0%-0.01
4	BondBloxx USD High Yield Bond Sector Rotation ETFHYSA	0%new
5	LUX - Tema ETF Trust - Tema Luxury ETF	——
6	Invesco Next Gen Connectivity ETFKNCT	0%0
7	RiverNorth Market Neutral ETFSPCZ	0%0
8	The Marcus CorporationMCS	-0%-0.09
9	FlexShares Morningstar U.S. Market Factor Tilt ETFTILT	0%0
10	Saba Capital Income & Opportunities Fund IISABA	0%new

Lumos Pharma, Inc.

Location

Social

What share of all stock conversation is about LUMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 19

*LUMO* has seen a sharp pullback from highs, with a current market cap of around 37.5K MC, and is undergoing consolidation.
The top holder of *LUMO* has a 5% stake, with some individual holding 8.5% through multiple wallets.
*LUMO* has experienced a strong recovery after a significant dip, retesting the 50K MC zone.

Generated by AI

Sentiment

Of the messages about LUMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.92% +10.02
Bearish	—	—	—	4.08% -10.02

Bullish· Feb 14

$LUMO is breaking ATHs and has a bullish chart, with over 550 holders and top 25 on DEX.
The project has a strong narrative, created by the same mind behind $Pippin, which touched 600M, suggesting similar potential.
Momentum is building, with the next leg expected to be huge, potentially reaching 500k and entering Big Whales territory.

Bearish· May 20

The release of the LumoKit has led to a sell-off in $LUMO, with early buyers quickly selling their shares.
The hype surrounding $LUMO has been short-lived, with the asset experiencing a significant price drop after the toolkit was shipped.
$LUMO's community has been criticized for being overly aggressive and confrontational, with some users accusing the team of being unresponsive to criticism and blocking users who speak out against them.

Generated by AI

Topics

Of the messages about LUMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	44.44%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	55.56%

Announcements· Dec 20

NewLink Genetics' Ebola vaccine, Ervebo, has been approved by the FDA for individuals 18 years and older.
The approval triggers a priority review voucher, which NewLink has a substantial economic interest in, and the company is expected to receive escalating royalties on sales.
The FDA's approval is a significant development for NewLink, with the company's stock surging over 7% in response, and is expected to provide substantial economic interest to the company.

Technical Analysis· Feb 21

$LUMO is in a downtrend with recent consolidation, with support around 0.0065 and resistance near 0.0090, and RSI approaching oversold levels.
$LUMO is showing bullish momentum with support around 0.0100 and resistance at 0.0125, with RSI above 70 and MACD showing a bullish crossover.
$LUMO is forming a potential double bottom pattern, indicating a possible upward breakout, with RSI rising and MACD showing a bullish crossover, and support around 0.010 and resistance at 0.015.

Generated by AI

Community

Of the messages about LUMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	22.47%
Newcomers	—	—	—	77.53%

Regulars· Nov 14

The interim results from two Phase 2 trials evaluating oral LUM-201 for moderate pediatric growth hormone deficiency showed an encouraging response, but the final analysis is awaited.
Lumos Pharma reported a loss of $0.86, which was better than the consensus estimate of ($1.01), and the company announced encouraging interim results from two Phase 2 trials.
The stock price declined by -22.4% after the company announced encouraging interim results from two Phase 2 trials evaluating oral LUM-201 for moderate pediatric growth hormone deficiency.

Newcomers· Feb 7

$LUMO is exhibiting a bullish chart, with a potential AI-driven parabola forming, according to some users.
The consolidation pattern in $LUMO's chart suggests potential upside if a certain support level holds, and some users are optimistic about its prospects.
$LUMO is among the AI stocks that some users are looking at for potential growth, alongside $SNAI and $NEUR.

Generated by AI

Lumos Pharma

Social

Mar 19

Sentiment

Bullish· Feb 14

Bearish· May 20

Topics

Announcements· Dec 20

Technical Analysis· Feb 21

Community

Regulars· Nov 14

Newcomers· Feb 7

Also Discussed

Lumos Pharma, Inc.

Company Information

Location

Also Discussed

Social

Mar 19

Sentiment

Bullish· Feb 14

Bearish· May 20

Topics

Announcements· Dec 20

Technical Analysis· Feb 21

Community

Regulars· Nov 14

Newcomers· Feb 7